Subscribe
Sign in
Latest
Top
Discussions
Counterfeit weight loss pens worth 2 million pounds seized in UK
A UK cohort study looked at tirzepatide treatment patterns around a price increase, and a separate cohort study found GLP-1 use associated with lower…
Oct 16
Lilly stock jumps 3.6% to crack IBD's Big Cap 20
Investor's Business Daily reports Eli Lilly shares rose 3.6% Thursday, joining its Big Cap 20 list of top-performing stocks.
Oct 16
1
Ireland weighs paying for more GLP-1 medications
The HSE is considering reimbursing more GLP-1s after receiving a number of applications, the Irish Times reports.
Oct 15
1
GLP-1 therapy tied to less psychiatric acute care in diabetes
An observational cohort study looked at adults with schizophrenia and type 2 diabetes, comparing GLP-1 therapy with DPP-4 and SGLT2 inhibitors.
Oct 15
Amgen plans a home-use trial for its injectable obesity drug
The autoinjector study has not started recruiting yet, with completion not expected until September 2027.
Oct 14
New semaglutide trial to track jobs, housing, run-ins with the law
STAT News reports a new trial of weekly semaglutide will track criminal justice involvement, employment, and housing stability, starting in early 2027.
Oct 14
1
Walmart plans no-cost Ozempic, Mounjaro for employees in 2027
CNBC reports Walmart plans to cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes such as Ozempic and Mounjaro…
Oct 13
1
Novo Nordisk registers phase 1 trial of switching to zenagamtide
The registered study has not started recruiting, and it asks how people on maintenance tirzepatide tolerate a switch.
Oct 13
1
GLP-1 aging research reported by New York Post on Oct. 11
Eli Lilly and Novo Nordisk presented research on GLP-1 medications and biological aging in overweight or diabetic patients, reported by the New York…
Oct 12
1
Eli Lilly v. Willow Health Services pending in Ninth Circuit
The docket does not say what the dispute is about, and its latest action is dated March 5, 2026.
Oct 11
NPR: Data on serious GLP-1 harms like blindness is scant
NPR reports that scant data on serious GLP-1 drug side effects makes it harder to answer scientific and legal questions about blindness and…
Oct 11
1
Second major U.K. health body cuts ties with Teva unit
A second major U.K. health body cut ties with a Teva Pharmaceuticals unit, plus GLP-1 aging clock data, food research and side effect questions.
Oct 10
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
